Embolischer Schlaganfall mit ungeklärter Emboliequelle (ESUS) – Klassifikation einer neuen Schlaganfallentität

Zusammenfassung

Als embolischer Schlaganfall mit ungeklärter Emboliequelle (ESUS) wird eine Subgruppe kryptogener Schlaganfälle bezeichnet, welche durch ein embolisches Infarktmuster definiert werden, wenn gleichzeitig trotz einer sorgfältig durchgeführten Diagnostik keine eindeutige und spezifische Emboliequelle identifiziert werden kann. In diesem Übersichtsartikel werden die Grundlagen des ESUS-Konzepts analysiert und ein Überblick über die Evidenz jüngster Kohortenstudien gegeben. Es werden die Definition, Ätiologie und die Diagnostik eines ESUS neu bewertet. Durch eine gezielte Diagnostik bei ESUS-Patienten kann die Anzahl kryptogener Schlaganfälle durch Stellen einer spezifischen Diagnose reduziert werden.

Abstract

Embolic stroke of undetermined source (ESUS) represents a subpopulation of cryptogenic strokes defined by its embolic stroke pattern on imaging and if after a carefully performed diagnostic evaluation, a specific, well recognized cause of stroke has not been identified. This review article analyses the basics of the ESUS concept and provides an overview of the evidence from recent cohort studies. The definition, aetiology and diagnosis of ESUS are reassessed. Targeted diagnostics in ESUS patients can reduce the number of cryptogenic strokes by making a specific diagnosis.

Schlüsselwörter

embolischer Schlaganfall ungeklärter Ursache - ESUS - Schlaganfallätiologie - Diagnose

Key words

embolic stroke of undetermined source - stroke etiology - diagnosis

Publikationsverlauf

Artikel online veröffentlicht:
18. März 2021

• Literatur

• 1 Adams H, Bendixen B. et al. Classification of Subtype of Acute Ischemic Stroke. Stroke 1993; 23: 35-41
• 2 Ji R, Schwamm LH, Pervez MA. et al. Ischemic stroke and transient ischemic attack in young adults: Risk factors, diagnostic yield, neuroimaging, and thrombolysis. Arch Neurol 2013; 70: 51-57
• 3 Saver JL. Cryptogenic stroke. N Engl J Med 2016; 374: 2065-2074
• 4 Hart RG, Diener HC, Coutts SB. et al. Embolic strokes of undetermined source: The case for a new clinical construct. Lancet Neurol 2014; 13: 429-438
• 5 Hart RG, Catanese L, Perera KS. et al. Embolic Stroke of Undetermined Source: A Systematic Review and Clinical Update. Stroke 2017; 48: 867-872
• 6 Boehme AK, Esenwa C, Elkind MSV. Stroke Risk Factors, Genetics, and Prevention. Circ Res 2017; 120: 472-495
• 7 Hart RG, Sharma M, Mundl H. et al. Rivaroxaban for stroke prevention after embolic stroke of undetermined source. N Engl J Med 2018; 378: 2191-2201
• 8 Diener HC, Sacco RL, Donald Easton J. et al. Dabigatran for prevention of stroke after embolic stroke of undetermined source. N Engl J Med 2019; 380: 1906-1917
• 9 Diener HC, Sacco RL, Easton JD. et al. Antithrombotic Treatment of Embolic Stroke of Undetermined Source. Stroke 2020; 51: 1758-1765
• 10 Ntaios G, Papavasileiou V, Milionis H. et al. Embolic Strokes of Undetermined Source in the Athens Stroke Registry. Stroke 2015; 46: 176-181
• 11 Ntaios G, Papavasileiou V, Milionis H. et al. Embolic Strokes of Undetermined Source in the Athens Stroke Registry: An Outcome Analysis. Stroke 2015; 46: 2087-2093
• 12 Kitsiou A, Rogalewski A, Kalyani M. et al Atrial fibrillation in patients with embolic stroke of undetermined source during 3 years of prolonged monitoring with an implantable loop recorder. Thromb Haemost 2020; Submitted
• 13 Ntaios G, Perlepe K, Lambrou D. et al Prevalence and Overlap of Potential Embolic Sources in Patients With Embolic Stroke of Undetermined Source. J Am Heart Assoc 2019; 8: e012858 . doi:10.1161/JAHA.119.012858
• 14 Ntaios G, Pearce LA, Meseguer E. et al. Aortic Arch Atherosclerosis in Patients With Embolic Stroke of Undetermined Source: An Exploratory Analysis of the NAVIGATE ESUS Trial. Stroke 2019; 50: 3184-3190
• 15 Ntaios G, Swaminathan B, Berkowitz SD. et al. Efficacy and Safety of Rivaroxaban Versus Aspirin in Embolic Stroke of Undetermined Source and Carotid Atherosclerosis. Stroke 2019; 50: 2477-2485
• 16 Siegler JE, Thon JM, Woo JH. et al Prevalence of Nonstenotic Carotid Plaque in Stroke Due to Atrial Fibrillation Compared to Embolic Stroke of Undetermined Source. J Stroke Cerebrovasc Dis 2019; 28 (10) 104289 doi:10.1016/j.jstrokecerebrovasdis. 2019.07.005
• 17 Ntaios G, Perlepe K, Sirimarco G. et al. Carotid plaques and detection of atrial fibrillation in embolic stroke of undetermined source. Neurology 2019; 92: e2644-e2652
• 18 Komatsu T, Iguchi Y, Arai A. et al. Large but nonstenotic carotid artery plaque in patients with a history of embolic stroke of undetermined source. Stroke 2018; 49: 3054-3056
• 19 Singh N, Moody AR, Panzov V. et al. Carotid Intraplaque Hemorrhage in Patients with Embolic Stroke of Undetermined Source. J Stroke Cerebrovasc Dis 2018; 27: 1956-1959
• 20 Tandon K, Tirschwell D, Longstreth WT. et al. Embolic stroke of undetermined source correlates to atrial fibrosis without atrial fibrillation. Neurology 2019; 93: E381-E387
• 21 Kamel H, Okin PM, Merkler AE. et al. Relationship between left atrial volume and ischemic stroke subtype. Ann Clin Transl Neurol 2019; 6: 1480-1486
• 22 Jordan K, Yaghi S, Poppas A. et al. Left Atrial Volume Index Is Associated with Cardioembolic Stroke and Atrial Fibrillation Detection after Embolic Stroke of Undetermined Source. Stroke 2019; 50: 1997-2001
• 23 Meisel K, Yuan K, Fang Q. et al. Embolic Stroke of Undetermined Source: A Population with Left Atrial Dysfunction. J Stroke Cerebrovasc Dis 2019; 28: 1891-1896
• 24 Takasugi J, Yamagami H, Noguchi T. et al. Detection of Left Ventricular Thrombus by Cardiac Magnetic Resonance in Embolic Stroke of Undetermined Source. Stroke 2017; 48: 2434-2440
• 25 Ohya Y, Osaki M, Fujimoto S. et al. Usefulness of Transesophageal Echocardiography for Predicting Covert Paroxysmal Atrial Fibrillation in Patients with Embolic Stroke of Undetermined Source. Cerebrovasc Dis Extra 2019; 9: 98-106
• 26 Kasner SE, Swaminathan B, Lavados P. et al. Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial. Lancet Neurol 2018; 17: 1053-1060
• 27 Ntaios G, Georgiopoulos G, Perlepe K. et al. A tool to identify patients with embolic stroke of undetermined source at high recurrence risk. Neurology 2019; 93: E2094-E2104
• 28 Moser M, Nitschmann S. Cardiovascular outcomes for people using anticoagulation strategies: COMPASS. Internist 2018; 59: 636-638
• 29 Sharma M, Hart RG, Connolly SJ. et al. Stroke Outcomes in the COMPASS Trial. Circulation 2019; 139: 1134-1145
• 30 Amarenco P, Labreuche J, Lavallée P. et al. Statins in stroke prevention and carotid atherosclerosis: Systematic review and up-to-date meta-analysis. Stroke 2004; 35: 2902-2909
• 31 Amarenco P, Bogousslavsky J, Callahan A. et al. High-Dose Atorvastatin after Stroke or Transient Ischemic Attack. N Engl J Med 2006; 355: 549-559
• 32 Vergouwen MDI, De Haan RJ, Vermeulen M. et al. Statin treatment and the occurrence of hemorrhagic stroke in patients with a history of cerebrovascular disease. Stroke 2008; 39: 497-502
• 33 Amarenco P, Kim JS, Labreuche J. et al. A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke. N Engl J Med 2020; 382: 9-19